Stock Index Futures Rise, Four Stocks to Watch
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy PFE?
Source: seekingalpha
- Strategy Stock Surge: Strategy (MSTR) shares jumped 9% in premarket trading despite posting a Q4 2025 GAAP EPS of -$42.93, significantly missing the -$20.99 analyst estimate due to unrealized losses on bitcoin holdings, which overshadowed a modest increase in software revenue and widened losses from -$3.03 in the same quarter last year.
- Pfizer Drug Application: Pfizer (PFE) shares were flat before the opening bell after the FDA granted priority review for its marketing application seeking label expansion for Hympavzi, a hemophilia therapy currently available for patients aged 12 and older, indicating potential growth in the hemophilia treatment market.
- Hims & Hers Stock Decline: Hims & Hers Health (HIMS) shares fell approximately 7% in early trading after FDA Commissioner announced swift action against companies mass-marketing illegal copycat drugs, which could impact Hims & Hers' business model that offers discounted compounded versions of Novo Nordisk's weight-loss therapy.
- Philip Morris Mixed Results: Philip Morris (PM) shares slipped 2.4% in premarket trading after reporting mixed Q4 results, with a non-GAAP EPS of $1.70 meeting estimates, but revenue of $10.36 billion, up 6.7% year-over-year, missed expectations by $40 million, while the company forecasts 2026 EPS between $7.87 and $8.02 with organic revenue growth of 5% to 7%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.56 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.490
Low
24.00
Averages
28.56
High
35.00
Current: 26.490
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Launches TrumpRx Program to Reduce Drug Costs
- Significant Drug Price Reductions: Pfizer's launch of the TrumpRx program offers substantial discounts on over 30 medications, with savings up to 85% and an average of 50%, aimed at alleviating the financial burden on American patients and enhancing their access to healthcare.
- Historic Agreement Support: This initiative is part of Pfizer's landmark Most Favored Nation agreement with the Trump administration, designed to lower prescription drug prices for U.S. patients while reinforcing America's leadership in global pharmaceutical innovation.
- Broad Patient Benefits: More than 100 million patients will benefit from discounted access to these medications, which treat a variety of conditions including migraines, rheumatoid arthritis, and menopause, significantly improving their quality of life and healthcare options.
- Enhanced Partnerships: Pfizer's collaboration with GoodRx allows patients to use coupons at nearly any U.S. pharmacy or opt for home delivery services, further increasing flexibility and convenience in accessing medications.
See More
Stock Index Futures Rise, Four Stocks to Watch
- Strategy Stock Surge: Strategy (MSTR) shares jumped 9% in premarket trading despite posting a Q4 2025 GAAP EPS of -$42.93, significantly missing the -$20.99 analyst estimate due to unrealized losses on bitcoin holdings, which overshadowed a modest increase in software revenue and widened losses from -$3.03 in the same quarter last year.
- Pfizer Drug Application: Pfizer (PFE) shares were flat before the opening bell after the FDA granted priority review for its marketing application seeking label expansion for Hympavzi, a hemophilia therapy currently available for patients aged 12 and older, indicating potential growth in the hemophilia treatment market.
- Hims & Hers Stock Decline: Hims & Hers Health (HIMS) shares fell approximately 7% in early trading after FDA Commissioner announced swift action against companies mass-marketing illegal copycat drugs, which could impact Hims & Hers' business model that offers discounted compounded versions of Novo Nordisk's weight-loss therapy.
- Philip Morris Mixed Results: Philip Morris (PM) shares slipped 2.4% in premarket trading after reporting mixed Q4 results, with a non-GAAP EPS of $1.70 meeting estimates, but revenue of $10.36 billion, up 6.7% year-over-year, missed expectations by $40 million, while the company forecasts 2026 EPS between $7.87 and $8.02 with organic revenue growth of 5% to 7%.
See More
Priovant Reports Positive Mid-Stage Trial Results for Brepocitinib in Cutaneous Sarcoidosis
- Clinical Trial Success: Priovant Therapeutics reported that its Phase 2 BEACON trial involving 31 cutaneous sarcoidosis patients demonstrated significant improvement in disease activity with 45 mg of brepocitinib after 16 weeks, with all patients showing at least a 10-point increase compared to 14% in the placebo group, indicating strong efficacy.
- Good Safety Profile: The trial revealed that brepocitinib had a well-tolerated safety profile, with all adverse events classified as mild or moderate and no serious adverse events reported, enhancing its market viability and attractiveness to investors.
- FDA Feedback Plans: Priovant intends to seek FDA feedback on these promising results and plans to initiate a Phase 3 clinical trial for the oral therapy in cutaneous sarcoidosis this year, reflecting the company's confidence in the drug's future market entry.
- Pfizer Investment Context: With Pfizer holding a 25% stake in Priovant, this investment not only provides financial backing but also strategically positions Pfizer to expand its footprint in the dermatological treatment market, leveraging Priovant's innovative therapies.
See More
Pfizer Seeks Label Expansion for Hemophilia Therapy Hympavzi
- Priority Review Granted: Pfizer announced that the FDA has granted priority review for its label expansion application for Hympavzi, indicating a significant advancement in the company's hemophilia treatment portfolio.
- Indication Expansion: The application aims to expand Hympavzi's indications to include patients aged six years and older with hemophilia A or B, which is expected to significantly enhance the drug's market potential and patient coverage.
- Current Market Status: Hympavzi is currently marketed in the U.S. for patients aged 12 and older, primarily for those without FVIII or FIX inhibitors, and the expansion will allow access for a broader pediatric population.
- FDA Decision Timeline: The FDA has set a target action date in Q2 2026 for this application, prompting Pfizer to align its market strategy around this timeline to ensure a successful launch of the new indications.
See More
Pfizer's HYMPAVZI Expands Indication for Hemophilia Treatment
- FDA Priority Review: Pfizer announced that the FDA has accepted the supplemental Biologics License Application for HYMPAVZI and granted Priority Review, with a decision expected in Q2 2026, which will provide new treatment options for patients aged 6 and older with hemophilia, addressing the urgent market need for non-factor prophylactic therapies.
- Innovative Pediatric Treatment: If approved, HYMPAVZI will become the first non-factor prophylactic treatment for children aged 6 to 11 without inhibitors, significantly improving the quality of life for these patients by reducing bleeding risks and filling a critical treatment gap.
- Clinical Trial Support: The application for HYMPAVZI is supported by efficacy and safety data from the BASIS clinical trial, demonstrating its potential to reduce bleeding frequency, particularly in inhibitor patients who are unresponsive to existing factor replacement therapies, highlighting its clinical significance.
- Global Market Outlook: HYMPAVZI has received regulatory approvals in over 40 countries as the first once-weekly subcutaneous prophylactic treatment, expected to drive Pfizer's market share growth in hemophilia treatment and further solidify its leadership position in the biopharmaceutical industry.
See More
Pfizer's HYMPAVZI Receives FDA Priority Review for Hemophilia Treatment
- FDA Priority Review: Pfizer's HYMPAVZI (marstacimab) has received FDA Priority Review to expand its indication for patients aged 6 and older with hemophilia A or B, with a decision expected in Q2 2026, which could provide a more effective treatment option and meet the urgent market demand for new therapies.
- Clinical Trial Support: The application for HYMPAVZI is supported by efficacy and safety data from the BASIS clinical trial, demonstrating its potential to reduce bleeding frequency, particularly in pediatric patients aged 6 to 11, which could transform the existing treatment landscape and enhance Pfizer's competitiveness in the hemophilia market.
- Treatment Need: Hemophilia affects over 800,000 people globally, with approximately 20% of hemophilia A patients and 3% of hemophilia B patients developing inhibitors, and the introduction of HYMPAVZI will provide new treatment options for these patients, addressing the current limitations in available therapies.
- Innovative Mechanism: HYMPAVZI targets tissue factor pathway inhibitor (TFPI) rather than traditional factor replacement therapies, offering a once-weekly subcutaneous injection that simplifies the treatment process, which is expected to improve patient adherence and quality of life, further solidifying Pfizer's leadership in the biopharmaceutical sector.
See More
Pfizer Launches TrumpRx Program to Reduce Drug Costs
- Significant Drug Price Reductions: Pfizer's launch of the TrumpRx program offers substantial discounts on over 30 medications, with savings up to 85% and an average of 50%, aimed at alleviating the financial burden on American patients and enhancing their access to healthcare.
- Historic Agreement Support: This initiative is part of Pfizer's landmark Most Favored Nation agreement with the Trump administration, designed to lower prescription drug prices for U.S. patients while reinforcing America's leadership in global pharmaceutical innovation.
- Broad Patient Benefits: More than 100 million patients will benefit from discounted access to these medications, which treat a variety of conditions including migraines, rheumatoid arthritis, and menopause, significantly improving their quality of life and healthcare options.
- Enhanced Partnerships: Pfizer's collaboration with GoodRx allows patients to use coupons at nearly any U.S. pharmacy or opt for home delivery services, further increasing flexibility and convenience in accessing medications.
See More
Stock Index Futures Rise, Four Stocks to Watch
- Strategy Stock Surge: Strategy (MSTR) shares jumped 9% in premarket trading despite posting a Q4 2025 GAAP EPS of -$42.93, significantly missing the -$20.99 analyst estimate due to unrealized losses on bitcoin holdings, which overshadowed a modest increase in software revenue and widened losses from -$3.03 in the same quarter last year.
- Pfizer Drug Application: Pfizer (PFE) shares were flat before the opening bell after the FDA granted priority review for its marketing application seeking label expansion for Hympavzi, a hemophilia therapy currently available for patients aged 12 and older, indicating potential growth in the hemophilia treatment market.
- Hims & Hers Stock Decline: Hims & Hers Health (HIMS) shares fell approximately 7% in early trading after FDA Commissioner announced swift action against companies mass-marketing illegal copycat drugs, which could impact Hims & Hers' business model that offers discounted compounded versions of Novo Nordisk's weight-loss therapy.
- Philip Morris Mixed Results: Philip Morris (PM) shares slipped 2.4% in premarket trading after reporting mixed Q4 results, with a non-GAAP EPS of $1.70 meeting estimates, but revenue of $10.36 billion, up 6.7% year-over-year, missed expectations by $40 million, while the company forecasts 2026 EPS between $7.87 and $8.02 with organic revenue growth of 5% to 7%.
See More
Priovant Reports Positive Mid-Stage Trial Results for Brepocitinib in Cutaneous Sarcoidosis
- Clinical Trial Success: Priovant Therapeutics reported that its Phase 2 BEACON trial involving 31 cutaneous sarcoidosis patients demonstrated significant improvement in disease activity with 45 mg of brepocitinib after 16 weeks, with all patients showing at least a 10-point increase compared to 14% in the placebo group, indicating strong efficacy.
- Good Safety Profile: The trial revealed that brepocitinib had a well-tolerated safety profile, with all adverse events classified as mild or moderate and no serious adverse events reported, enhancing its market viability and attractiveness to investors.
- FDA Feedback Plans: Priovant intends to seek FDA feedback on these promising results and plans to initiate a Phase 3 clinical trial for the oral therapy in cutaneous sarcoidosis this year, reflecting the company's confidence in the drug's future market entry.
- Pfizer Investment Context: With Pfizer holding a 25% stake in Priovant, this investment not only provides financial backing but also strategically positions Pfizer to expand its footprint in the dermatological treatment market, leveraging Priovant's innovative therapies.
See More
Pfizer Seeks Label Expansion for Hemophilia Therapy Hympavzi
- Priority Review Granted: Pfizer announced that the FDA has granted priority review for its label expansion application for Hympavzi, indicating a significant advancement in the company's hemophilia treatment portfolio.
- Indication Expansion: The application aims to expand Hympavzi's indications to include patients aged six years and older with hemophilia A or B, which is expected to significantly enhance the drug's market potential and patient coverage.
- Current Market Status: Hympavzi is currently marketed in the U.S. for patients aged 12 and older, primarily for those without FVIII or FIX inhibitors, and the expansion will allow access for a broader pediatric population.
- FDA Decision Timeline: The FDA has set a target action date in Q2 2026 for this application, prompting Pfizer to align its market strategy around this timeline to ensure a successful launch of the new indications.
See More
Pfizer's HYMPAVZI Expands Indication for Hemophilia Treatment
- FDA Priority Review: Pfizer announced that the FDA has accepted the supplemental Biologics License Application for HYMPAVZI and granted Priority Review, with a decision expected in Q2 2026, which will provide new treatment options for patients aged 6 and older with hemophilia, addressing the urgent market need for non-factor prophylactic therapies.
- Innovative Pediatric Treatment: If approved, HYMPAVZI will become the first non-factor prophylactic treatment for children aged 6 to 11 without inhibitors, significantly improving the quality of life for these patients by reducing bleeding risks and filling a critical treatment gap.
- Clinical Trial Support: The application for HYMPAVZI is supported by efficacy and safety data from the BASIS clinical trial, demonstrating its potential to reduce bleeding frequency, particularly in inhibitor patients who are unresponsive to existing factor replacement therapies, highlighting its clinical significance.
- Global Market Outlook: HYMPAVZI has received regulatory approvals in over 40 countries as the first once-weekly subcutaneous prophylactic treatment, expected to drive Pfizer's market share growth in hemophilia treatment and further solidify its leadership position in the biopharmaceutical industry.
See More
Pfizer's HYMPAVZI Receives FDA Priority Review for Hemophilia Treatment
- FDA Priority Review: Pfizer's HYMPAVZI (marstacimab) has received FDA Priority Review to expand its indication for patients aged 6 and older with hemophilia A or B, with a decision expected in Q2 2026, which could provide a more effective treatment option and meet the urgent market demand for new therapies.
- Clinical Trial Support: The application for HYMPAVZI is supported by efficacy and safety data from the BASIS clinical trial, demonstrating its potential to reduce bleeding frequency, particularly in pediatric patients aged 6 to 11, which could transform the existing treatment landscape and enhance Pfizer's competitiveness in the hemophilia market.
- Treatment Need: Hemophilia affects over 800,000 people globally, with approximately 20% of hemophilia A patients and 3% of hemophilia B patients developing inhibitors, and the introduction of HYMPAVZI will provide new treatment options for these patients, addressing the current limitations in available therapies.
- Innovative Mechanism: HYMPAVZI targets tissue factor pathway inhibitor (TFPI) rather than traditional factor replacement therapies, offering a once-weekly subcutaneous injection that simplifies the treatment process, which is expected to improve patient adherence and quality of life, further solidifying Pfizer's leadership in the biopharmaceutical sector.
See More
